explore -WSS

explore

author：entertainment 2025-09-27 17:02:24 - browse：29

A sign of The Cigna Group in front of trees with orange and green leaves — insurance overage from STAT — Joe Buglewicz/Bloomberg

Cigna and Humana are in discussions to merge, a potential move that would create a health insurance and prescription drug benefits titan with approximately $300 billion of annual revenue.

A proposed transaction would almost certainly prompt a close review from antitrust enforcers at the Department of Justice and the Federal Trade Commission. A merged Cigna-Humana would further consolidate the market for pharmacy benefit managers. PBMs are companies that serve as the controversial middlemen of drug pricing negotiations, and of the four largest, two are owned by Cigna and Humana.

The Wall Street Journal first reported the talks between Cigna and Humana on Wednesday, citing sources close to the situation. Wendell Potter, a health insurance whistleblower who used to work at Cigna, also wrote about merger discussions between Cigna and Humana on his blog Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Medicare will require more price transparency from hospitals

WSS

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Leading voice in opioid treatment defends methadone clinic system

Diversify hospital leadership teams to protect BIPOC patient health

Leading voice in opioid treatment defends methadone clinic system

Excited delirium, Elijah McClain, and emergency physicians

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

knowledge

explore

hotspot

ChatGPT in medicine: STAT answers readers' burning questions

Sanofi CEO defends move to abandon profit guidance, boost research

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Bluebird, CVS, Contineum

As demand for Covid shots wanes, Moderna seeks its next success

Methadone treatment changes are coming. Do they go far enough?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Argenx readies a blockbuster opportunity with drug for autoimmune disease

DIEP, the 'gold standard' of breast reconstruction, is under threat

Victims of gun violence feel impacts long after bullet wound

hotspot

UCSF medical school apologizes for unethical prisoner experiments

Will General Catalyst be the first of many hospital takeovers?

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

A clever new way to fix Medicaid and graduate medical education

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Plastic surgeons increase patient psychiatric screenings

Wikipedia

explore

knowledge

hotspot